HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

Frontiers in Immunology

Immunology

Xiaoming Hou¹  Xin Jiang¹  Chen Shen¹  Yao Luo¹  Mei Li¹  Fulai Xue¹  Yinan Zhang²  Yujuan Duan³ 

[1] Department of Laboratory Medicine, Medical Equipment Innovation Research Center/Medical Device Regulatory Research and Evaluation Center, West China Hospital, Sichuan University, Chengdu, China;School of Chemical Science and Engineering, Tongji University, Shanghai, China;School of Chemical Science and Engineering, Tongji University, Shanghai, China;School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai, China;

关键词: hepatocellular carcinoma;    tumor immune microenvironment;    immunotherapy;    immune checkpoint inhibitors;    HDAC inhibitors;    nano-based drug delivery system;   

DOI  :  10.3389/fimmu.2023.1170207

 received in 2023-02-21, accepted in 2023-05-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma (HCC), the most common liver malignancy with a poor prognosis and increasing incidence, remains a serious health problem worldwide. Immunotherapy has been described as one of the ideal ways to treat HCC and is transforming patient management. However, the occurrence of immunotherapy resistance still prevents some patients from benefiting from current immunotherapies. Recent studies have shown that histone deacetylase inhibitors (HDACis) can enhance the efficacy of immunotherapy in a variety of tumors, including HCC. In this review, we present current knowledge and recent advances in immunotherapy-based and HDACi-based therapies for HCC. We highlight the fundamental dynamics of synergies between immunotherapies and HDACis, further detailing current efforts to translate this knowledge into clinical benefits. In addition, we explored the possibility of nano-based drug delivery system (NDDS) as a novel strategy to enhance HCC treatment.

【 授权许可】

Unknown   
Copyright © 2023 Shen, Li, Duan, Jiang, Hou, Xue, Zhang and Luo